Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 1/20 | 0.78 |
| ▸ | TP53 | P04637 | 1/20 | 0.78 |
| ▸ | HTT | P42858 | 1/20 | 0.78 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.78 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.78 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.78 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | PIM1 | P11309 | 1/20 | 0.55 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.55 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.55 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.55 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.55 |
| ▸ | NT5E | P21589 | 1/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.52 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5064888 | 1.00 | PNP (0.78) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL5983251 | 1.00 | PNP (0.78) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL5983802 | 0.89 | LMNA (0.79) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL5983804 | 0.89 | LMNA (0.79) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL6560256 | 0.89 | LMNA (0.79) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL23982227 | 0.89 | LMNA (0.79) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL6560259 | 0.89 | LMNA (0.79) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL27968166 | 0.89 | LMNA (0.79) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL10438039 | 0.88 | PNP (0.64) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL855722 | 0.88 | PNP (0.64) | PNPLMNATP53HTTPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158425-A1 | MODIFIED ADENINES | NUCLERA LTD (GB) | 2024-05-16 | — | — | US | disclosed |
| WO-2022175684-A1 | MODIFIED ADENINES | NUCLERA NUCLEICS LTD (GB) | 2022-08-25 | — | — | WO | disclosed |
| US-8680062-B2 | System for delivering therapeutic agents into living cells and cells nuclei | Deliversir Ltd. (IL) | 2014-03-25 | — | — | US | disclosed |
| US-20080004234-A1 | System for delivering therapeutic agents into living cells and cells nuclei | SEGEV LABORATORIES LIMITED (IL) | 2008-01-03 | — | — | US | disclosed |
| WO-2007135380-A2 | ANTIPARASITIC COMPOUNDS AND COMPOSITIONS | MEDICAL RESEARCH COUNCIL (GB) | 2007-11-29 | — | — | WO | disclosed |
| US-20070142317-A1 | Topical composition for treatment of skin disorders | QLT USA, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20060160763-A1 | System for delivering therapeutic agents into living cells and cells nuclei | SEGEV LABORATORIES LIMITED (IL) | 2006-07-20 | — | — | US | disclosed |
| WO-2006010084-A2 | A SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELL NUCLEI | SEGEV LABORATORIES LIMITED (IL) | 2006-01-26 | — | — | WO | disclosed |
| WO-2005065668-A2 | TOPICAL COMPOSITIONS COMPRISING HALO-DEOXYADENOSINES FOR TREATMENT OF SKIN DISORDERS | QLT USA, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| EP-0604409-B1 | OLIGONUCLEOTIDE ANALOGS FOR DETECTING AND MODULATING RNA ACTIVITY AND GENE EXPRESSION | ISIS PHARMACEUTICALS INC (US) | 2004-07-14 | — | — | EP | disclosed |
| US-5459255-A | For incorporation into oligonucleotides, cleaving RNA site specifically | ISIS PHARMACEUTICALS, INC. (US) | 1995-10-17 | — | — | US | disclosed |
| WO-1995021184-A1 | SUBSTITUTED PURINES AND OLIGONUCLEOTIDE CROSS-LINKING | ISIS PHARMACEUTICALS, INC. (US) | 1995-08-10 | — | — | WO | disclosed |
| WO-1995014707-A1 | N-2 SUBSTITUTED PURINES | ISIS PHARMACEUTICALS, INC. (US) | 1995-06-01 | — | — | WO | disclosed |
| EP-0604409-A1 | COMPOSITIONS AND METHODS FOR DETECTING AND MODULATING RNA ACTIVITY AND GENE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1994-07-06 | — | — | EP | disclosed |
| EP-0203959-B1 | NUCLEOTIDE ANALOGS FOR NUCLEIC ACID LABELING AND DETECTION | LIFE TECHNOLOGIES, INC. (US) | 1992-09-09 | — | — | EP | disclosed |
| WO-1991010671-A1 | COMPOSITIONS AND METHODS FOR DETECTING AND MODULATING RNA ACTIVITY AND GENE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1991-07-25 | — | — | WO | disclosed |
| EP-0203959-A4 | NUCLEOTIDE ANALOGS FOR NUCLEIC ACID LABELING AND DETECTION. | LIFE TECHNOLOGIES INC (US) | 1989-08-09 | — | — | EP | disclosed |
| US-4828979-A | BIOTINYLATED | LIFE TECHNOLOGIES, INC. (US) | 1989-05-09 | — | — | US | disclosed |
| EP-0203959-A1 | NUCLEOTIDE ANALOGS FOR NUCLEIC ACID LABELING AND DETECTION. | LIFE TECHNOLOGIES INC (US) | 1986-12-10 | — | — | EP | disclosed |
| WO-1986002929-A1 | NUCLEOTIDE ANALOGS FOR NUCLEIC ACID LABELING AND DETECTION | LIFE TECHNOLOGIES, INC. (US) | 1986-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142317-A1 | Topical composition for treatment of skin disorders | CDA, ADA, DCTD | PNP 14/4885LMNA 3214/4885TP53 2160/4885 |
| US-20240158425-A1 | MODIFIED ADENINES | RNGTT, ADAR, MRM1 | PNP 16/4885LMNA 680/4885TP53 2221/4885 |
| US-20060160763-A1 | System for delivering therapeutic agents into living cells and cells nuclei | RCC1, NUMA1, ACIN1 | PNP 2386/4885LMNA 107/4885TP53 98/4885 |
| US-20080004234-A1 | System for delivering therapeutic agents into living cells and cells nuclei | RCC1, NUMA1, ACIN1 | PNP 2386/4885LMNA 107/4885TP53 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.